The burden of hypertensive heart disease in China and G20 countries: analysis from 1990 to 2021 and 30-year projections for China

Both China and the G20 group exhibit a pronounced upward trend in HHD prevalence and mortality, likely attributable to the backdrop of population aging. Conversely, China's declining prevalence and mortality rates may benefit from advances in medical technology. Furthermore, China's ASPR is projected to increase annually over the next 30 years. These findings underscore the imperative to strengthen prevention, control, and treatment strategies, providing crucial evidence for healthcare planning and practice.